{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00022947", "CSN": null, "TRF": "ORD_1445637_01", "MRN": "48757831", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1189060", "clinicalId": "1190430", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1445637_01", "SampleName": "US1385740.01", "Version": "0", "Sample": {"FM_Id": "ORD_1445637_01", "SampleId": "US1385740.01", "BlockId": "S111-30418A", "TRFNumber": "ORD_1445637_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_08_29", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "50", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-97881", "MRN": "48757831", "FullName": "\u5f35\u5149\u8000", "FirstName": "Kuang_Yao", "LastName": "Chang", "SubmittedDiagnosis": "Gliosarcoma, Cerebrum", "Gender": "Male", "DOB": "1973_09_05", "OrderingMD": "\u8a31\u79c9\u6b0a", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Brain", "CollDate": "2022_08_09", "ReceivedDate": "2022-09-13 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Diffuse Glioma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "14", "clinicalTrialCount": "24", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "APC", "isVUS": "true", "variantName": "V1125A"}, {"geneName": "ARID1A", "isVUS": "true", "variantName": "A162T"}, {"geneName": "CD22", "isVUS": "true", "variantName": "E518K"}, {"geneName": "CDK4", "isVUS": "true", "variantName": "rearrangement"}, {"geneName": "CREBBP", "isVUS": "true", "variantName": "Q278P"}, {"geneName": "MDM2", "isVUS": "true", "variantName": "rearrangement,rearrangement,rearrangement"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "CDK4", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "CDK4 encodes the cyclin_dependent kinase 4, which regulates the cell cycle, senescence, and apoptosis (reviewed in Choi et al., 2014; 23644662). CDK4 and its functional homolog CDK6 are activated by D_type cyclins and promote cell cycle progression by inactivating the tumor suppressor Rb (Weinberg et al., 1995; 7736585, Musgrove et al., 2011; 21734724). Amplification of the chromosomal region that includes CDK4 has been reported in multiple cancer types, including lung cancer, glioblastoma, and liposarcoma, and has been associated with overexpression of CDK4 protein (Wikman et al., 2005; 15543620, Rao et al., 2010; 19609742, Dickson et al., 2013; 23569312, Chung et al., 2009; 19574885, Ragazzini et al., 2004; 15024701, Dujardin et al., 2011; 21336260, Zhang et al., 2013; 23393200, Horvai et al., 2009; 19734852). CDK4 amplification has been observed in 9.4% of glioma cases (cBio_Jonsson et al., 2019; 31263031). A study has reported amplification of the 12q14_15 region, where CDK4 and MDM2 reside, in 4.8% (2/42) of glioblastomas (Zheng et al., 2013; 23796897). Amplification of CDK4 and corresponding increased CDK4 protein expression has been reported to be associated with a poorer patient outcome in anaplastic astrocytoma and glioblastoma (Kim et al., 2010; 20080666, Ruano et al., 2009; 19141386, Fischer et al., 2008; 18403636, B\u00e4cklund et al., 2005; 15970925). CDK4 amplification or activation may predict sensitivity to CDK4/6 inhibitors such as abemaciclib, palbociclib, and ribociclib (Dickson et al., 2013; 23569312, Flaherty et al., 2012; 22090362, Patnaik et al., 2016; 27217383, Infante et al., 2016; 27542767). Clinical benefit has been reported for limited tumor types including patients with CDK4_amplified liposarcoma and sarcoma in response to treatment with abemaciclib (Dickson et al., 2019; ASCO Abstract 11004), palbociclib (Dickson et al., 2013; 23569312, Dickson et al., 2016; 27124835), and ribociclib (Peguero et al., 2016; ASCO Abstract 2528).", "Include": "true", "ClinicalTrialNote": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04282031", "Include": "true"}, {"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT02933736", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT05159245", "Include": "true"}, {"nctId": "NCT03994796", "Include": "true"}, {"nctId": "NCT04116541", "Include": "true"}, {"nctId": "NCT02981940", "Include": "true"}, {"nctId": "NCT05252416", "Include": "true"}, {"nctId": "NCT02896335", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "MDM2", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "amplification"}}, "Interpretation": "MDM2 encodes an E3 ubiquitin protein ligase, which mediates the ubiquitination and subsequent degradation of p53, Rb1, and other proteins (Sdek et al., 2005; 16337594, Brady et al., 2005; 15632057, Li et al., 2004; 15053880). MDM2 acts to prevent the activity of the tumor suppressor p53; therefore, overexpression or amplification of MDM2 may be oncogenic (Brown et al., 2009; 19935675, Cordon_Cardo et al., 1994; 8306343). Overexpression or amplification of MDM2 is frequent in cancer (Beroukhim et al., 2010; 20164920). Although two retrospective clinical studies suggest that MDM2 amplification may predict a short time_to_treatment failure on anti_PD_1/PD_L1 immune checkpoint inhibitors, with 4/5 patients with MDM2 amplification (Kato et al., 2017; 28351930) and 2/3 patients with MDM2 or MDM4 amplification (Singavi et al., 2017; ESMO Abstract 1140PD) experiencing tumor hyperprogression, amplification of MDM2 or MDM4 was not associated with shorter progression_free survival (PFS) in a retrospective analysis of non_small cell lung cancer (NSCLC) outcomes with immune checkpoint inhibitors (hazard ratio of 1.4, p=0.44)(Rizvi et al., 2018; 29337640). The latter study reported PFS of >2 months for 5/8 patients with MDM2/MDM4 amplification (Rizvi et al., 2018; 29337640). MDM2 amplification was reported in 8% (3/38) of gliosarcomas in one study (Actor et al., 2002; 12112531). In the Glioblastoma Multiforme (GBM) TCGA dataset, amplification of MDM2 has been found in 8% of cases (cBio_Brennan et al., 2013; 24120142). A study has reported amplification of the 12q14_15 region, where MDM2 and CDK4 reside, in 5% (2/42) of GBMs (Zheng et al., 2013; 23796897). Amplification of MDM2 has been associated with poor survival in patients with glioblastoma (Fischer et al., 2010; 19839052, Zheng et al., 2013; 23796897). MDM2 antagonists disrupt the MDM2_p53 interaction, thereby stabilizing p53 (Cheok et al., 2011; 20975744). Preclinical studies have suggested that the amplification of MDM2, in the absence of concurrent TP53 mutations, may increase sensitivity to these agents (Ohnstad et al., 2013; 23165797, Gamble et al., 2012; 21725357). Preliminary Phase 1 studies of the MDM2_p53 antagonist alrizomadlin (APG_115) reported a PR in a patient with liposarcoma harboring an MDM2 amplification and wildtype for TP53 and SD in 21%\u201338% (6/28 and 5/13, respectively) of patients in genomically unselected solid tumors (Zhang et al., 2019; ASCO Abstract 3124, Rasco et al., 2019; ASCO Abstract 3126). A Phase 2 trial of alrizomadlin in combination with pembrolizumab reported a PR in 1 of 3 patients with malignant peripheral nerve sheath tumor that had failed standard therapy, as well as PRs in patients with multiple types of solid tumors that had failed immunotherapy, including 1 out of 14 patients with non_small cell lung cancer; 1 out of 5 patients with urothelial carcinoma; and 2 out of5, 1 out of 5, and 1 out of 11 patients with mucosal, uveal, and cutaneous melanoma, respectively (Tolcher et al., 2021; ASCO Abstract 2506). Phase 1b studies of the MDM2 inhibitor idasanutlin for refractory AML in combination with cytarabine or venetoclax reported anti_leukemic response rates of 33% (25/75) and 37% (11/30), respectively (Martinelli et al., 2016; EHA21 Abstract S504, Daver et al., 2018; ASH Abstract 767); clinical benefit (58% ORR, 7/12) with idasanutlin monotherapy has been reported for patients with polycythemia vera (Mascarenhas et al., 2019; ASH Abstract 134). The dual MDM2/MDM4 inhibitor ALRN_6924 led to an ORR of 27% (4/15) for patients with TP53 wildtype peripheral T_cell lymphoma in a Phase 2 study (Shustov et al., 2018; ASH Abstract 1623); responses have also been observed in TP53 wildtype AML, MDS, Merkel cell carcinoma, colorectal cancer, and liposarcoma (Sallman et al., 2018; ASH Abstract 4066, Meric_Bernstam et al., 2017; ASCO Abstract 2505).", "Include": "true", "ClinicalTrialNote": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04589845", "Include": "true"}, {"nctId": "NCT04785196", "Include": "true"}, {"nctId": "NCT03449381", "Include": "true"}, {"nctId": "NCT03611868", "Include": "true"}, {"nctId": "NCT03725436", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PTEN", "Include": "true", "Alterations": {"Alteration": {"Name": "M270fs*28", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "M270fs*28"}}, "Interpretation": "PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K_AKT_mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis (Simpson and Parsons, 2001; 11237521). Alterations such as seen here may disrupt PTEN function or expression (Campbell et al., 2003; 12857747, Rodr\u00edguez_Escudero et al., 2011; 21828076, He et al., 2013; 23475934, Han et al., 2000; 10866302, Myers et al., 1998; 9811831, Pradella et al., 2014; 24498881, Kim et al., 2011; 21536651, Denning et al., 2007; 17213812, Hlobilkova et al., 2006; 16619501, Redfern et al., 2010; 20718038, Shenoy et al., 2012; 22505997, Wang et al., 2009; 19329485, Okumura et al., 2006; 16829519, Lee et al., 1999; 10555148, Maxwell et al., 1998; 9635567, Risinger et al., 1998; 9865913, Kato et al., 2000; 11051241, Fenton et al, 2012; 22891331, Ngeow et al., 2012; 23066114, Lobo et al., 2009; 19457929, Liu et al., 2014; 23995781, Maehama et al., 2001; 11395408, De Vivo et al., 2000; 10807691, Ramaswamy et al., 1999; 10051603, Liu et al., 2005; 15988030, Karoui et al., 2004; 15026806, Gil et al., 2015; 25875300, Furnari et al., 1998; 9823298, Spinelli et al., 2015; 25527629, Mingo et al., 2018; 29706633, Wang et al., 2010; 20538496, Andr\u00e9s_Pons et al., 2007; 17942903, Butler et al., 2005; 15805158, Lee et al., 1999; 10555148, Georgescu et al., 1999; 10468583, Staal et al., 2002; 12085208, Nguyen et al., 2013; 24292679, Rahdar et al., 2009; 19114656, Das et al., 2003; 12808147, Wang et al., 2008; 18498243, Valiente et al., 2005; 15951562, Nguyen et al., 2015; 25263454, Shan et al., 2020; 32704382). PTEN mutations have been observed in 37% (7/19) to 50% (15/30) of gliosarcomas in small studies (Actor et al., 2002; 12112531, Reis et al., 2000; 10666371, Zaki et al., 2021; 34504233). Studies in the literature have indicated that PTEN alterations (mutation or homozygous deletion) occur most frequently in glioblastoma (GBM), less frequently in anaplastic astrocytoma, and rarely in lower grade glioma subtypes including low grade astrocytoma, oligodendroglioma, oligoastrocytoma, and ependymoma (Zhou et al., 1999; 10096247, Rasheed et al., 1997; 9331072, Davies et al., 1999; 10188904, Smith et al., 2001; 11504770, Lin et al., 1998; 9796977, Schmidt et al., 1999; 10560660, Kato et al., 2000; 11051241, Furnari et al., 2007; 17974913). One study detected PTEN mutation in 42% (97/232) and loss in 10% (24/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). In the TCGA dataset, PTEN mutation was observed in 23% of GBM cases and PTEN deletion was reported in 7% of cases (cBio_Brennan et al., 2013; 24120142), while in the Lower Grade Glioma TCGA dataset, PTEN mutation was observed in 4% of cases and homozygous deletion observed in 1.2% of cases (Cancer Genome Atlas Research Network., 2015; 26061751). Loss of PTEN correlated with significantly worse prognosis in all grades of gliomas (Lin et al., 1998; 9796977, Srividya et al., 2011; 21134002). PTEN loss or mutation leads to activation of the PI3K_AKT_mTOR pathway and may predict sensitivity to inhibitors of this pathway (Courtney et al., 2010; 20085938, Simpson and Parsons, 2001; 11237521, Patnaik et al., 2016; 27672108, Milella et al., 2017; 28220839). Across various tissues, most clinical studies have not observed an association between PTEN deficiency and response to inhibitors of the PI3K_AKT_mTOR pathway. However, limited studies in prostate cancer (Templeton et al., 2013; 23582881, Sweeney et al., 2021; 34246347, de Bono et al., 2019; 30037818, Saura et al., 2017; 27872130), renal cell carcinoma (Voss et al., 2019; 30327302), breast cancer (Andre et al., 2016; 27091708, Dent et al., 2018; ASCO Abstract 1008, Schmid et al., 2020; 31841354), and colorectal cancer (Gilcrease et al., 2019; 30302599) have reported an association between PTEN deficiency and response to inhibitors targeting the PI3K_AKT_mTOR pathway. Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors (Mendes_Pereira et al., 2009; 20049735, Shen et al., 2013; 23881923, Chatterjee et al., 2013; 23565244, McCormick et al., 2016; 26905328, Forster et al., 2011; 21468130), and clinical benefit has been observed for patients with PTEN_altered breast cancer including triple negative breast cancer (Gruber et al., 2019; ASCO Abstract 3006, Eikesdal et al., 2021; 33242536), ovarian cancer (Dougherty et al., 2014; ASCO Abstract 5536), uterine leiomyosarcoma (Pan et al., 2021; 33970096), and endometrial cancer (Forster et al., 2011; 21468130) treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity (Sandhu et al., 2013; 23810788, Romero et al., 2020; 32988624, Piha_Paul et al., 2018; AACR Abstract A096). PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte_Duclos disease (LD), Bannayan_Riley_Ruvalcaba syndrome (BRRS), PTEN_related Proteus syndrome (PS), and Proteus_like syndrome (Blumenthal and Dennis, 2008; 18781191, Orloff and Eng, 2008; 18794875). The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients (Blumenthal and Dennis, 2008; 18781191, Zbuk and Eng, 2007; 17167516). The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder (Blumenthal and Dennis, 2008; 18781191). Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.", "Include": "true", "ClinicalTrialNote": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04644068", "Include": "true"}, {"nctId": "NCT04341259", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04740190", "Include": "true"}, {"nctId": "NCT04001569", "Include": "true"}, {"nctId": "NCT05035745", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT05076513", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). Low_level MSI has been reported in 5_9% of glioblastoma (GBM) samples (Martinez et al., 2004; 15331927, Martinez et al., 2005; 15672285, Martinez et al., 2007; 17498554). A large_scale study did not find high_level microsatellite instability (MSI_H) in any of 129 GBM samples (Martinez et al., 2004; 15331927), although a small_scale study reported MSI_H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs (Szybka et al., 2003; 12908754). The frequency of MSI has been reported to be increased in relapsed compared to primary GBM (Martinez et al., 2004; 15331927), in GBMs with a previous lower grade astrocytoma (Martinez et al., 2005; 15672285), and in giant cell GBM compared to classic GBM (Martinez et al., 2007; 17498554). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TERT", "Include": "true", "Alterations": {"Alteration": {"Name": "promoter _124C>T", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "promoter _124C>T"}}, "Interpretation": "Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length (Shay et al., 2011; 22015685). Activation of TERT is a hallmark of cancer, being detected in up to 80_90% of malignancies and absent in quiescent cells (Shay et al., 1997; 9282118, Kim et al., 1994; 7605428, Hanahan and Weinberg, 2000; 10647931). Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at _124 bp and _146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)(Horn et al., 2013; 23348503, Huang et al., 2014; 23348506, Vinagre et al., 2013; 23887589), as well as tandem mutations at positions \u2013124/\u2013125 bp and \u2013138/\u2013139 bp (Horn et al., 2013; 23348503). TERT promoter mutations have been reported in 51_59% of gliomas (Killela et al., 2013; 23530248, Killela et al., 2014; 24722048), most frequently in glioblastoma (GBM, 54_84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25_31%) but less frequently in lower grade astrocytomas (10_18%) and in only 1% of ependymomas (Nonoguchi et al., 2013; 23955565, Liu et al., 2013; 23603989, Koelsche et al., 2013; 24154961, Killela et al., 2013; 23530248, Killela et al., 2014; 24722048). TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM (Arita et al., 2013; 23764841). TERT promoter mutations significantly associate with poor prognosis in patients with GBM, although this correlation may be due to the association with primary GBM as opposed to IDH_positive secondary GBM (Killela et al., 2013; 23530248, Nonoguchi et al., 2013; 23955565, Reitman et al., 2013; 24217890, Arita et al., 2013; 23764841). In the context of IDH_wildtype glioma, TERT mutations are associated with reduced OS (NCCN CNS Cancers Guidelines, v1.2022). Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor_associated antigen and antisense oligonucleotide_ or peptide_based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials (Zanetti et al., 2017; 27245281); however, in one preclinical study, the combination of a TERT peptide vaccine and anti_CTLA_4 therapy suppressed tumor growth (Duperret at al., 2018; 29249395). A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non_small cell lung cancer reported no improvement in PFS or OS (Chiappori et al., 2015; 25467017). TERT mutations are associated with 1p/19q co_deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX_wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v1.2022)(Weller et al., 2020; 33293629).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "00", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "00"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Touat et al., 2020; 32322066, Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556, Lukas et al., 2018; 30073642). Gliosarcoma harbors a median TMB of 3.6 mutations per megabase (muts/Mb), and 2% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). For pediatric patients, high TMB has been reported in a subset of high_grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB (Patel et al., 2020; 32386112, Johnson et al., 2017; 28912153). Increased TMB has been reported to correlate with higher tumor grade in glioma (Draaisma et al., 2015; 26699864) and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD) (Bouffet et al., 2016; 27001570), as well as with shorter OS of patients with diffuse glioma (Wang et al., 2020; 32164609). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported (Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Touat et al., 2020; 32322066). However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti_PD_1 (Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556) or anti_PD_L1 (Lukas et al., 2018; 30073642) therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD_1 or PD_L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "CDK4", "Alteration": "amplification", "Title": "A Study of BPI_1178 in Patients With Advanced Solid Tumor and HR+/HER2_ Breast Cancer", "StudyPhase": "PHASE 1/2", "Target": "CDK6, CDK4, ER, Aromatase", "Locations": "Shanghai (China)", "NCTID": "NCT04282031", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients", "StudyPhase": "PHASE null", "Target": "CDK6, CDK4", "Locations": "Arizona", "NCTID": "NCT02933736", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "The Finnish National Study to Facilitate Patient Access to Targeted Anti_cancer Drugs", "StudyPhase": "PHASE 2", "Target": "BRAF, VEGFRs, RET, KIT, ERBB2, TRKB, ALK, TRKC, ROS1, TRKA, SMO, PD_L1, MEK, CDK4, CDK6", "Locations": "Kuopio (Finland), Helsinki (Finland), Tampere (Finland), Turku (Finland)", "NCTID": "NCT05159245", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR", "Locations": "Washington, Oregon, Idaho, Montana", "NCTID": "NCT03994796", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "A Study Evaluating the Activity of Anti_cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.", "StudyPhase": "PHASE 2", "Target": "CDK6, CDK4, MDM2, MET, ROS1, RET, VEGFRs", "Locations": "Nice (France), Lyon (France), Marseille (France), Toulouse (France), Bordeaux (France)", "NCTID": "NCT04116541", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "A Study of Abemaciclib in Recurrent Glioblastoma", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6", "Locations": "Utah, California, Massachusetts", "NCTID": "NCT02981940", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "(VELA) Study of BLU_222 in Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ER, CDK4, CDK6, CDK2", "Locations": "Massachusetts, Texas, Florida", "NCTID": "NCT05252416", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CDK4", "Alteration": "amplification", "Title": "Palbociclib In Progressive Brain Metastases", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT02896335", "Note": "CDK4 amplification may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha", "Locations": "Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Shanghai City (China), Shanghai (China), Shatin (Hong Kong), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi an (China), Tianjin (China)", "NCTID": "NCT04589845", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "APG_115 in Combination With PD_1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "PD_1, MDM2", "Locations": "Shanghai (China), Guangzhou (China)", "NCTID": "NCT04785196", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)", "StudyPhase": "PHASE 1", "Target": "MDM2", "Locations": "Tokyo, Chuo_ku (Japan), Warsaw (Poland), Poznan (Poland), Berlin (Germany), K\u00f6ln (Germany), T\u00fcbingen (Germany), Leuven (Belgium), Barcelona (Spain), California, Ottawa (Canada)", "NCTID": "NCT03449381", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "A Study of APG_115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "MDM2, PD_1", "Locations": "Brisbane (Australia), South Brisbane (Australia), Bedford Park (Australia), Heidelberg (Australia), California, Arizona, Missouri, Arkansas, Ohio, Pennsylvania", "NCTID": "NCT03611868", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "MDM2", "Alteration": "amplification", "Title": "ALRN_6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MDM2, MDM4", "Locations": "Texas", "NCTID": "NCT03725436", "Note": "Inhibitors of the MDM2_p53 interaction are being tested in clinical trials. Overexpression or amplification of MDM2 may increase sensitivity to these agents, but more data are required.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "M270fs*28", "Title": "Study of AZD5305 as Monotherapy and in Combination With Anti_cancer Agents in Patients With Advanced Solid Malignancies", "StudyPhase": "PHASE 1/2", "Target": "ERBB2, TROP2, PARP", "Locations": "Shanghai (China), Seoul (Korea, Republic of), Chongqing (China), Chuo_ku (Japan), Koto_ku (Japan), Melbourne (Australia), Warszawa (Poland), Gdynia (Poland), Grzepnica (Poland), Budapest (Hungary)", "NCTID": "NCT04644068", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "M270fs*28", "Title": "A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.", "StudyPhase": "PHASE 1", "Target": "AKTs", "Locations": "Shanghai City (China)", "NCTID": "NCT04341259", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "M270fs*28", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "M270fs*28", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT02264678", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "M270fs*28", "Title": "Talazoparib _ Carboplatin for Recurrent High_grade Glioma With DDRd", "StudyPhase": "PHASE 2", "Target": "PARP", "Locations": "Hong Kong (Hong Kong)", "NCTID": "NCT04740190", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "M270fs*28", "Title": "AZD8186 and Paclitaxel in Advanced Gastric Cancer", "StudyPhase": "PHASE 1/2", "Target": "PI3K_beta", "Locations": "Seongnam_si (Korea, Republic of)", "NCTID": "NCT04001569", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "M270fs*28", "Title": "Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)", "StudyPhase": "PHASE 1/2", "Target": "XPO1, PARP", "Locations": "Singapore (Singapore)", "NCTID": "NCT05035745", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "M270fs*28", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "M270fs*28", "Title": "Trial of Niraparib in Participants With Newly_diagnosed Glioblastoma and Recurrent Glioma", "StudyPhase": "PHASE null", "Target": "PARP", "Locations": "Arizona", "NCTID": "NCT05076513", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}, {"Gene": "PTEN", "Alteration": "M270fs*28", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PTEN loss or inactivating mutations may lead to increased activation of the PI3K_AKT_mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "23644662", "FullCitation": "Choi YJ, et al. Oncogene (2014) pmid: 23644662", "Include": "true"}, {"number": "1", "ReferenceId": "7736585", "FullCitation": "Cell (1995) pmid: 7736585", "Include": "true"}, {"number": "2", "ReferenceId": "21734724", "FullCitation": "Musgrove EA, et al. Nat. Rev. Cancer (2011) pmid: 21734724", "Include": "true"}, {"number": "3", "ReferenceId": "15543620", "FullCitation": "Wikman H, et al. Genes Chromosomes Cancer (2005) pmid: 15543620", "Include": "true"}, {"number": "4", "ReferenceId": "19609742", "FullCitation": "Rao SK, et al. J. Neurooncol. (2010) pmid: 19609742", "Include": "true"}, {"number": "5", "ReferenceId": "23569312", "FullCitation": "Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312", "Include": "true"}, {"number": "6", "ReferenceId": "19574885", "FullCitation": "Chung L, et al. Am. J. Surg. Pathol. (2009) pmid: 19574885", "Include": "true"}, {"number": "7", "ReferenceId": "15024701", "FullCitation": "Ragazzini P, et al. Histol. Histopathol. (2004) pmid: 15024701", "Include": "true"}, {"number": "8", "ReferenceId": "21336260", "FullCitation": "Dujardin F, et al. Mod. Pathol. (2011) pmid: 21336260", "Include": "true"}, {"number": "9", "ReferenceId": "23393200", "FullCitation": "Zhang K, et al. Cancer Res. (2013) pmid: 23393200", "Include": "true"}, {"number": "10", "ReferenceId": "19734852", "FullCitation": "Horvai AE, et al. Mod. Pathol. (2009) pmid: 19734852", "Include": "true"}, {"number": "11", "ReferenceId": "31263031", "FullCitation": "Jonsson P, et al. Clin. Cancer Res. (2019) pmid: 31263031", "Include": "true"}, {"number": "12", "ReferenceId": "23796897", "FullCitation": "Zheng S, et al. Genes Dev. (2013) pmid: 23796897", "Include": "true"}, {"number": "13", "ReferenceId": "20080666", "FullCitation": "Kim H, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20080666", "Include": "true"}, {"number": "14", "ReferenceId": "19141386", "FullCitation": "Ruano Y, et al. Am. J. Clin. Pathol. (2009) pmid: 19141386", "Include": "true"}, {"number": "15", "ReferenceId": "18403636", "FullCitation": "Fischer U, et al. Mol. Cancer Res. (2008) pmid: 18403636", "Include": "true"}, {"number": "16", "ReferenceId": "15970925", "FullCitation": "B\u00e4cklund LM, et al. Br. J. Cancer (2005) pmid: 15970925", "Include": "true"}, {"number": "17", "ReferenceId": "22090362", "FullCitation": "Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362", "Include": "true"}, {"number": "18", "ReferenceId": "27217383", "FullCitation": "Patnaik A, et al. Cancer Discov (2016) pmid: 27217383", "Include": "true"}, {"number": "19", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "20", "ReferenceId": "27124835", "FullCitation": "Dickson MA, et al. JAMA Oncol (2016) pmid: 27124835", "Include": "true"}, {"number": "21", "ReferenceId": "16337594", "FullCitation": "Sdek P, et al. Mol. Cell (2005) pmid: 16337594", "Include": "true"}, {"number": "22", "ReferenceId": "15632057", "FullCitation": "Brady M, et al. Mol. Cell. Biol. (2005) pmid: 15632057", "Include": "true"}, {"number": "23", "ReferenceId": "15053880", "FullCitation": "Li M, et al. Mol. Cell (2004) pmid: 15053880", "Include": "true"}, {"number": "24", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "25", "ReferenceId": "8306343", "FullCitation": "Cordon_Cardo C, et al. Cancer Res. (1994) pmid: 8306343", "Include": "true"}, {"number": "26", "ReferenceId": "20164920", "FullCitation": "Beroukhim R, et al. Nature (2010) pmid: 20164920", "Include": "true"}, {"number": "27", "ReferenceId": "28351930", "FullCitation": "Kato S, et al. Clin. Cancer Res. (2017) pmid: 28351930", "Include": "true"}, {"number": "28", "ReferenceId": "29337640", "FullCitation": "Rizvi H, et al. J. Clin. Oncol. (2018) pmid: 29337640", "Include": "true"}, {"number": "29", "ReferenceId": "12112531", "FullCitation": "Actor B, et al. Genes Chromosomes Cancer (2002) pmid: 12112531", "Include": "true"}, {"number": "30", "ReferenceId": "24120142", "FullCitation": "Brennan CW, et al. Cell (2013) pmid: 24120142", "Include": "true"}, {"number": "31", "ReferenceId": "19839052", "FullCitation": "Fischer U, et al. Int. J. Cancer (2010) pmid: 19839052", "Include": "true"}, {"number": "32", "ReferenceId": "20975744", "FullCitation": "Cheok CF, et al. Nat Rev Clin Oncol (2011) pmid: 20975744", "Include": "true"}, {"number": "33", "ReferenceId": "23165797", "FullCitation": "Ohnstad HO, et al. Cancer (2013) pmid: 23165797", "Include": "true"}, {"number": "34", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "35", "ReferenceId": "11237521", "FullCitation": "Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521", "Include": "true"}, {"number": "36", "ReferenceId": "12857747", "FullCitation": "Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747", "Include": "true"}, {"number": "37", "ReferenceId": "21828076", "FullCitation": "Rodr\u00edguez_Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076", "Include": "true"}, {"number": "38", "ReferenceId": "23475934", "FullCitation": "He X, et al. Cancer Res. (2013) pmid: 23475934", "Include": "true"}, {"number": "39", "ReferenceId": "10866302", "FullCitation": "Han SY, et al. Cancer Res. (2000) pmid: 10866302", "Include": "true"}, {"number": "40", "ReferenceId": "9811831", "FullCitation": "Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831", "Include": "true"}, {"number": "41", "ReferenceId": "24498881", "FullCitation": "Pradella LM, et al. BMC Cancer (2014) pmid: 24498881", "Include": "true"}, {"number": "42", "ReferenceId": "21536651", "FullCitation": "Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651", "Include": "true"}, {"number": "43", "ReferenceId": "17213812", "FullCitation": "Denning G, et al. Oncogene (2007) pmid: 17213812", "Include": "true"}, {"number": "44", "ReferenceId": "16619501", "FullCitation": "Hlobilkova A, et al. Anticancer Res. () pmid: 16619501", "Include": "true"}, {"number": "45", "ReferenceId": "20718038", "FullCitation": "Redfern RE, et al. Protein Sci. (2010) pmid: 20718038", "Include": "true"}, {"number": "46", "ReferenceId": "22505997", "FullCitation": "Shenoy S, et al. PLoS ONE (2012) pmid: 22505997", "Include": "true"}, {"number": "47", "ReferenceId": "19329485", "FullCitation": "Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485", "Include": "true"}, {"number": "48", "ReferenceId": "16829519", "FullCitation": "Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519", "Include": "true"}, {"number": "49", "ReferenceId": "10555148", "FullCitation": "Lee JO, et al. Cell (1999) pmid: 10555148", "Include": "true"}, {"number": "50", "ReferenceId": "9635567", "FullCitation": "Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567", "Include": "true"}, {"number": "51", "ReferenceId": "9865913", "FullCitation": "Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913", "Include": "true"}, {"number": "52", "ReferenceId": "11051241", "FullCitation": "Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241", "Include": "true"}, {"number": "53", "ReferenceId": "22891331", "FullCitation": "Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331", "Include": "true"}, {"number": "54", "ReferenceId": "23066114", "FullCitation": "Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114", "Include": "true"}, {"number": "55", "ReferenceId": "19457929", "FullCitation": "Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929", "Include": "true"}, {"number": "56", "ReferenceId": "23995781", "FullCitation": "Liu J, et al. Oncogene (2014) pmid: 23995781", "Include": "true"}, {"number": "57", "ReferenceId": "11395408", "FullCitation": "Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408", "Include": "true"}, {"number": "58", "ReferenceId": "10807691", "FullCitation": "De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691", "Include": "true"}, {"number": "59", "ReferenceId": "10051603", "FullCitation": "Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603", "Include": "true"}, {"number": "60", "ReferenceId": "15988030", "FullCitation": "Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030", "Include": "true"}, {"number": "61", "ReferenceId": "15026806", "FullCitation": "Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806", "Include": "true"}, {"number": "62", "ReferenceId": "25875300", "FullCitation": "Gil A, et al. PLoS ONE (2015) pmid: 25875300", "Include": "true"}, {"number": "63", "ReferenceId": "9823298", "FullCitation": "Furnari FB, et al. Cancer Res. (1998) pmid: 9823298", "Include": "true"}, {"number": "64", "ReferenceId": "25527629", "FullCitation": "Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629", "Include": "true"}, {"number": "65", "ReferenceId": "29706633", "FullCitation": "Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633", "Include": "true"}, {"number": "66", "ReferenceId": "20538496", "FullCitation": "Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496", "Include": "true"}, {"number": "67", "ReferenceId": "17942903", "FullCitation": "Andr\u00e9s_Pons A, et al. Cancer Res. (2007) pmid: 17942903", "Include": "true"}, {"number": "68", "ReferenceId": "15805158", "FullCitation": "Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158", "Include": "true"}, {"number": "69", "ReferenceId": "10468583", "FullCitation": "Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583", "Include": "true"}, {"number": "70", "ReferenceId": "12085208", "FullCitation": "Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208", "Include": "true"}, {"number": "71", "ReferenceId": "24292679", "FullCitation": "Nguyen HN, et al. Oncogene (2014) pmid: 24292679", "Include": "true"}, {"number": "72", "ReferenceId": "19114656", "FullCitation": "Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656", "Include": "true"}, {"number": "73", "ReferenceId": "12808147", "FullCitation": "Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147", "Include": "true"}, {"number": "74", "ReferenceId": "18498243", "FullCitation": "Wang X, et al. Biochem. J. (2008) pmid: 18498243", "Include": "true"}, {"number": "75", "ReferenceId": "15951562", "FullCitation": "Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562", "Include": "true"}, {"number": "76", "ReferenceId": "25263454", "FullCitation": "Nguyen HN, et al. Oncogene (2015) pmid: 25263454", "Include": "true"}, {"number": "77", "ReferenceId": "32704382", "FullCitation": "Shan L, et al. Cell Discov (2020) pmid: 32704382", "Include": "true"}, {"number": "78", "ReferenceId": "10666371", "FullCitation": "Reis RM, et al. Am. J. Pathol. (2000) pmid: 10666371", "Include": "true"}, {"number": "79", "ReferenceId": "34504233", "FullCitation": "Zaki MM, et al. Sci Rep (2021) pmid: 34504233", "Include": "true"}, {"number": "80", "ReferenceId": "10096247", "FullCitation": "Zhou XP, et al. Int. J. Cancer (1999) pmid: 10096247", "Include": "true"}, {"number": "81", "ReferenceId": "9331072", "FullCitation": "Rasheed BK, et al. Cancer Res. (1997) pmid: 9331072", "Include": "true"}, {"number": "82", "ReferenceId": "10188904", "FullCitation": "Davies MP, et al. Br. J. Cancer (1999) pmid: 10188904", "Include": "true"}, {"number": "83", "ReferenceId": "11504770", "FullCitation": "Smith JS, et al. J. Natl. Cancer Inst. (2001) pmid: 11504770", "Include": "true"}, {"number": "84", "ReferenceId": "9796977", "FullCitation": "Lin H, et al. Clin. Cancer Res. (1998) pmid: 9796977", "Include": "true"}, {"number": "85", "ReferenceId": "10560660", "FullCitation": "Schmidt EE, et al. J. Neuropathol. Exp. Neurol. (1999) pmid: 10560660", "Include": "true"}, {"number": "86", "ReferenceId": "17974913", "FullCitation": "Furnari FB, et al. Genes Dev. (2007) pmid: 17974913", "Include": "true"}, {"number": "87", "ReferenceId": "26061751", "FullCitation": "Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751", "Include": "true"}, {"number": "88", "ReferenceId": "21134002", "FullCitation": "Srividya MR, et al. Neuropathology (2011) pmid: 21134002", "Include": "true"}, {"number": "89", "ReferenceId": "20085938", "FullCitation": "Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938", "Include": "true"}, {"number": "90", "ReferenceId": "27672108", "FullCitation": "Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108", "Include": "true"}, {"number": "91", "ReferenceId": "28220839", "FullCitation": "Milella M, et al. Sci Rep (2017) pmid: 28220839", "Include": "true"}, {"number": "92", "ReferenceId": "23582881", "FullCitation": "Templeton AJ, et al. Eur. Urol. (2013) pmid: 23582881", "Include": "true"}, {"number": "93", "ReferenceId": "34246347", "FullCitation": "Sweeney C, et al. Lancet (2021) pmid: 34246347", "Include": "true"}, {"number": "94", "ReferenceId": "30037818", "FullCitation": "de Bono JS, et al. Clin. Cancer Res. (2019) pmid: 30037818", "Include": "true"}, {"number": "95", "ReferenceId": "27872130", "FullCitation": "Saura C, et al. Cancer Discov (2017) pmid: 27872130", "Include": "true"}, {"number": "96", "ReferenceId": "30327302", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2018) pmid: 30327302", "Include": "true"}, {"number": "97", "ReferenceId": "27091708", "FullCitation": "Andr\u00e9 F, et al. J. Clin. Oncol. (2016) pmid: 27091708", "Include": "true"}, {"number": "98", "ReferenceId": "31841354", "FullCitation": "Schmid P, et al. J. Clin. Oncol. (2019) pmid: 31841354", "Include": "true"}, {"number": "99", "ReferenceId": "30302599", "FullCitation": "Weldon Gilcrease G, et al. Invest New Drugs (2019) pmid: 30302599", "Include": "true"}, {"number": "100", "ReferenceId": "20049735", "FullCitation": "Mendes_Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735", "Include": "true"}, {"number": "101", "ReferenceId": "23881923", "FullCitation": "Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923", "Include": "true"}, {"number": "102", "ReferenceId": "23565244", "FullCitation": "Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244", "Include": "true"}, {"number": "103", "ReferenceId": "26905328", "FullCitation": "McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328", "Include": "true"}, {"number": "104", "ReferenceId": "21468130", "FullCitation": "Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130", "Include": "true"}, {"number": "105", "ReferenceId": "33242536", "FullCitation": "Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536", "Include": "true"}, {"number": "106", "ReferenceId": "33970096", "FullCitation": "Pan M, et al. Perm J (2021) pmid: 33970096", "Include": "true"}, {"number": "107", "ReferenceId": "23810788", "FullCitation": "Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788", "Include": "true"}, {"number": "108", "ReferenceId": "32988624", "FullCitation": "Romero I, et al. Gynecol Oncol (2020) pmid: 32988624", "Include": "true"}, {"number": "109", "ReferenceId": "18781191", "FullCitation": "Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191", "Include": "true"}, {"number": "110", "ReferenceId": "18794875", "FullCitation": "Orloff MS, et al. Oncogene (2008) pmid: 18794875", "Include": "true"}, {"number": "111", "ReferenceId": "17167516", "FullCitation": "Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516", "Include": "true"}, {"number": "112", "ReferenceId": "22015685", "FullCitation": "Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685", "Include": "true"}, {"number": "113", "ReferenceId": "9282118", "FullCitation": "Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118", "Include": "true"}, {"number": "114", "ReferenceId": "7605428", "FullCitation": "Kim NW, et al. Science (1994) pmid: 7605428", "Include": "true"}, {"number": "115", "ReferenceId": "10647931", "FullCitation": "Hanahan D, et al. Cell (2000) pmid: 10647931", "Include": "true"}, {"number": "116", "ReferenceId": "23348503", "FullCitation": "Horn S, et al. Science (2013) pmid: 23348503", "Include": "true"}, {"number": "117", "ReferenceId": "23348506", "FullCitation": "Huang FW, et al. Science (2013) pmid: 23348506", "Include": "true"}, {"number": "118", "ReferenceId": "23887589", "FullCitation": "Vinagre J, et al. Nat Commun (2013) pmid: 23887589", "Include": "true"}, {"number": "119", "ReferenceId": "23530248", "FullCitation": "Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23530248", "Include": "true"}, {"number": "120", "ReferenceId": "24722048", "FullCitation": "Killela PJ, et al. Oncotarget (2014) pmid: 24722048", "Include": "true"}, {"number": "121", "ReferenceId": "23955565", "FullCitation": "Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565", "Include": "true"}, {"number": "122", "ReferenceId": "23603989", "FullCitation": "Liu X, et al. Cell Cycle (2013) pmid: 23603989", "Include": "true"}, {"number": "123", "ReferenceId": "24154961", "FullCitation": "Koelsche C, et al. Acta Neuropathol. (2013) pmid: 24154961", "Include": "true"}, {"number": "124", "ReferenceId": "23764841", "FullCitation": "Arita H, et al. Acta Neuropathol. (2013) pmid: 23764841", "Include": "true"}, {"number": "125", "ReferenceId": "24217890", "FullCitation": "Reitman ZJ, et al. Acta Neuropathol. (2013) pmid: 24217890", "Include": "true"}, {"number": "126", "ReferenceId": "27245281", "FullCitation": "Nat Rev Clin Oncol (2017) pmid: 27245281", "Include": "true"}, {"number": "127", "ReferenceId": "29249395", "FullCitation": "Duperret EK, et al. Mol Ther (2018) pmid: 29249395", "Include": "true"}, {"number": "128", "ReferenceId": "25467017", "FullCitation": "Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017", "Include": "true"}, {"number": "129", "ReferenceId": "33293629", "FullCitation": "Weller M, et al. Nat Rev Clin Oncol (2021) pmid: 33293629", "Include": "true"}, {"number": "130", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "131", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "132", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "133", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "134", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "135", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "136", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "137", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "138", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "139", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "140", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "141", "ReferenceId": "32322066", "FullCitation": "Touat M, et al. Nature (2020) pmid: 32322066", "Include": "true"}, {"number": "142", "ReferenceId": "30742119", "FullCitation": "Zhao J, et al. Nat. Med. (2019) pmid: 30742119", "Include": "true"}, {"number": "143", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "144", "ReferenceId": "27001570", "FullCitation": "Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570", "Include": "true"}, {"number": "145", "ReferenceId": "27683556", "FullCitation": "Johanns TM, et al. Cancer Discov (2016) pmid: 27683556", "Include": "true"}, {"number": "146", "ReferenceId": "30073642", "FullCitation": "Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642", "Include": "true"}, {"number": "147", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "148", "ReferenceId": "32386112", "FullCitation": "Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112", "Include": "true"}, {"number": "149", "ReferenceId": "28912153", "FullCitation": "Johnson A, et al. Oncologist (2017) pmid: 28912153", "Include": "true"}, {"number": "150", "ReferenceId": "26699864", "FullCitation": "Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864", "Include": "true"}, {"number": "151", "ReferenceId": "32164609", "FullCitation": "Wang L, et al. BMC Cancer (2020) pmid: 32164609", "Include": "true"}, {"number": "152", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "153", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "154", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "155", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "156", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "157", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "158", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "159", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "160", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "161", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "162", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "163", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "164", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "165", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "166", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "167", "ReferenceId": "15331927", "FullCitation": "Martinez R, et al. Oncology (2004) pmid: 15331927", "Include": "true"}, {"number": "168", "ReferenceId": "15672285", "FullCitation": "Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285", "Include": "true"}, {"number": "169", "ReferenceId": "17498554", "FullCitation": "Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554", "Include": "true"}, {"number": "170", "ReferenceId": "12908754", "FullCitation": "Szybka M, et al. Clin. Neuropathol. () pmid: 12908754", "Include": "true"}, {"number": "171", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "172", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "173", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "174", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_09_09 20:23:00", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "787x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "0 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BRAIN", "disease_ontology": "Brain gliosarcoma", "flowcell_analysis": "2000023438", "gender": "male", "pathology_diagnosis": "Gliosarcoma", "percent_tumor_nuclei": "50", "pipeline_version": "v3.13.0", "purity_assessment": "44.7", "specimen": "ORD_1445637_01*US1385740.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1445637_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Brain", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "808.83", "name": "SQ_US1385740.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.2153", "cds_effect": "_124C>T", "depth": "209", "equivocal": "false", "functional_effect": "promoter", "gene": "TERT", "percent_reads": "21.53", "position": "chr5:1295228", "protein_effect": "promoter _124C>T", "status": "known", "strand": "_", "transcript": "NM_198253", "dna_evidence": {"sample": "SQ_US1385740.01_1"}}, {"allele_fraction": "0.2909", "cds_effect": "808_809insA", "depth": "110", "equivocal": "false", "functional_effect": "frameshift", "gene": "PTEN", "percent_reads": "29.09", "position": "chr10:89720657", "protein_effect": "M270fs*28", "status": "likely", "strand": "+", "transcript": "NM_000314", "dna_evidence": {"sample": "SQ_US1385740.01_1"}}, {"allele_fraction": "0.4888", "cds_effect": "3374T>C", "depth": "984", "equivocal": "false", "functional_effect": "missense", "gene": "APC", "percent_reads": "48.88", "position": "chr5:112174665", "protein_effect": "V1125A", "status": "unknown", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1385740.01_1"}}, {"allele_fraction": "0.4324", "cds_effect": "484G>A", "depth": "296", "equivocal": "false", "functional_effect": "missense", "gene": "ARID1A", "percent_reads": "43.24", "position": "chr1:27023378", "protein_effect": "A162T", "status": "unknown", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1385740.01_1"}}, {"allele_fraction": "0.5178", "cds_effect": "1552G>A", "depth": "647", "equivocal": "false", "functional_effect": "missense", "gene": "CD22", "percent_reads": "51.78", "position": "chr19:35832290", "protein_effect": "E518K", "status": "unknown", "strand": "+", "transcript": "NM_001771", "dna_evidence": {"sample": "SQ_US1385740.01_1"}}, {"allele_fraction": "0.4869", "cds_effect": "833A>C", "depth": "534", "equivocal": "false", "functional_effect": "missense", "gene": "CREBBP", "percent_reads": "48.69", "position": "chr16:3860746", "protein_effect": "Q278P", "status": "unknown", "strand": "_", "transcript": "NM_004380", "dna_evidence": {"sample": "SQ_US1385740.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "55", "equivocal": "false", "gene": "MDM2", "number_of_exons": "11 of 11", "position": "chr12:69153996_69277205", "ratio": "12.13", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1385740.01_1"}}, {"copy_number": "61", "equivocal": "false", "gene": "CDK4", "number_of_exons": "7 of 7", "position": "chr12:58093932_58188144", "ratio": "13.64", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1385740.01_1"}}]}, "rearrangements": {"rearrangement": [{"description": "MDM2(NM_002392) rearrangement exon 9", "equivocal": "false", "in_frame": "unknown", "other_gene": "CPM", "pos1": "chr12:69229459_69229667", "pos2": "chr12:69324215_69324341", "status": "unknown", "supporting_read_pairs": "1541", "targeted_gene": "MDM2", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1385740.01_1"}}, {"description": "CDK4(NM_000075) rearrangement exon 2", "equivocal": "false", "in_frame": "unknown", "other_gene": "N/A", "pos1": "chr12:58145228_58145399", "pos2": "chr12:69190699_69191049", "status": "unknown", "supporting_read_pairs": "213", "targeted_gene": "CDK4", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1385740.01_1"}}, {"description": "MDM2(NM_002392) rearrangement exon 9", "equivocal": "false", "in_frame": "unknown", "other_gene": "TRHDE", "pos1": "chr12:69229463_69229667", "pos2": "chr12:73052585_73052763", "status": "unknown", "supporting_read_pairs": "323", "targeted_gene": "MDM2", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1385740.01_1"}}, {"description": "MDM2(NM_002392) rearrangement exon 9", "equivocal": "false", "in_frame": "unknown", "other_gene": "N/A", "pos1": "chr12:69229666", "pos2": "chr12:57875464", "status": "unknown", "supporting_read_pairs": "109", "targeted_gene": "MDM2", "type": "rearrangement", "dna_evidence": {"sample": "SQ_US1385740.01_1"}}]}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "0.0", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}